CPTC-EGFR-6 (CAB080312)

Uniprot ID: P00533

Protein name: EGFR HUMAN

Full name: Epidermal growth factor receptor

Tissue specificity: Ubiquitously expressed. Isoform 2 is also expressed in ovarian cancers.

Function: Receptor tyrosine kinase binding ligands of the EGF family and activating several signaling cascades to convert extracellular cues into appropriate cellular responses (PubMed:2790960, PubMed:10805725, PubMed:27153536). Known ligands include EGF, TGFA/TGF-alpha, AREG, epigen/EPGN, BTC/betacellulin, epiregulin/EREG and HBEGF/heparin-binding EGF (PubMed:2790960, PubMed:7679104, PubMed:8144591, PubMed:9419975, PubMed:15611079, PubMed:12297049, PubMed:27153536, PubMed:20837704, PubMed:17909029). Ligand binding triggers receptor homo- and/or heterodimerization and autophosphorylation on key cytoplasmic residues. The phosphorylated receptor recruits adapter proteins like GRB2 which in turn activates complex downstream signaling cascades. Activates at least 4 major downstream signaling cascades including the RAS-RAF-MEK-ERK, PI3 kinase-AKT, PLCgamma-PKC and STATs modules (PubMed:27153536). May also activate the NF-kappa-B signaling cascade (PubMed:11116146). Also directly phosphorylates other proteins like RGS16, activating its GTPase activity and probably coupling the EGF receptor signaling to the G protein-coupled receptor signaling (PubMed:11602604). Also phosphorylates MUC1 and increases its interaction with SRC and CTNNB1/beta-catenin (PubMed:11483589). Positively regulates cell migration via interaction with CCDC88A/GIV which retains EGFR at the cell membrane following ligand stimulation, promoting EGFR signaling which triggers cell migration (PubMed:20462955). Plays a role in enhancing learning and memory performance (By similarity). Isoform 2 may act as an antagonist of EGF action. (Microbial infection) Acts as a receptor for hepatitis C virus (HCV) in hepatocytes and facilitates its cell entry. Mediates HCV entry by promoting the formation of the CD81-CLDN1 receptor complexes that are essential for HCV entry and by enhancing membrane fusion of cells expressing HCV envelope glycoproteins.

Subcellular location

Unnamed:

Cell membrane (experimental evidence) (Topo: Single-pass type I membrane protein (experimental evidence))

Endoplasmic reticulum membrane (experimental evidence) (Topo: Single-pass type I membrane protein)

Golgi apparatus membrane (Topo: Single-pass type I membrane protein)

Nucleus membrane (Topo: Single-pass type I membrane protein)

Endosome (experimental evidence)

Endosome membrane

Nucleus (experimental evidence)


NOTE: In response to EGF, translocated from the cell membrane to the nucleus via Golgi and ER (PubMed:20674546, PubMed:17909029). Endocytosed upon activation by ligand (PubMed:2790960, PubMed:17182860, PubMed:27153536, PubMed:17909029). Colocalized with GPER1 in the nucleus of estrogen agonist-induced cancer-associated fibroblasts (CAF) (PubMed:20551055).

Isoform 2: Secreted

Protein existence: Experimental evidence at protein level


Comment:

Immunohistochemistry




| IHC protocol: | HIER pH6, Dilution 1:600 |
|--------------------------|--|
| IHC test staining: | No positivity was observed. |
| Literature conformance: | Not consistent with gene/protein characterization data |
| Literature significance: | |
| RNA similarity: | Very low consistency between antibody staining and RNA expression data |
| RNA tissue specificity: | Low tissue specificity |
| RNA tissue distribution: | Detected in many |
| IHC Sibling similarity: | Other antibody shows dissimilar IHC staining pattern |

Immunofluorescence



| IF Overlay: | antibody (green), anti-tubulin (red) and DAPI (blue) |
|-------------------------------------|--|
| IF main location: | |
| IF additional location: | |
| IF approved for publication on HPA: | No |
| IF in THP-1: | Negative |
| IF in U2OS: | Negative |

Western blot



| WB Size markers (kDa): | 250, 130, 100, 70, 55, 35, 25, 15, 10 | |
|-------------------------|---|--|
| WB Lanes: | Marker (1), RT-4 (2), U-251MG (3), Plasma (4), Liver (5), Tonsil (6) | |
| WB Target weight (kDa): | 15, 45, 69, 77, 121, 129, 134 | |
| WB Validation: | Supported (Band of predicted size in kDa (+/-20%) with additional bands present.) | |